AlphaFold predicted structure
BMPR2 · Q13873

Mean pLDDT
57.4/ 100
Low
1,038 residues
Confidence breakdown
- Very high(≥ 90)26%
- Confident(70–90)12%
- Low(50–70)5%
- Very low(< 50)57%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
bone morphogenetic protein receptor type 2
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Childhood interstitial lung disease
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedPulmonary arterial hypertension
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownHereditary haemorrhagic telangiectasia
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedExtreme early-onset hypertension
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedFamilial pulmonary fibrosis
pulmonary hypertension, primary, 1
pulmonary arterial hypertension
pulmonary venoocclusive disease
pulmonary venoocclusive disease 1
idiopathic pulmonary arterial hypertension
heritable pulmonary arterial hypertension
Pulmonary arterial hypertension associated with congenital heart disease
bone disorder
genetic non-acquired premature ovarian failure
spondylolisthesis
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Bone morphogenetic protein receptor type-2
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Can also mediate signaling through the activation of the p38MAPK cascade (PubMed:12045205). Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6. Promotes signaling also by binding to activin A/INHBA (PubMed:24018044)
BMPR2 · Q13873

Mean pLDDT
57.4/ 100
Low
1,038 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0